Bio-Rad Laboratories, Inc.

NYQ: BIO
Live Quote

📈 ZcoreAI Score

Our AI model analyzes Bio-Rad Laboratories, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get BIO Z-Score →

About Bio-Rad Laboratories, Inc.

Healthcare Medical Devices
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

📊 Fundamental Analysis

Bio-Rad Laboratories, Inc. demonstrates exceptional profitability, with a profit margin of 29.4%.

The company recently reported 3.9% revenue growth, which is modest compared to its industry peers.

Return on Equity (ROE) is 10.8%, which suggests room for improvement in capital utilization.

At a current price of $279.25, BIO currently sits at the 51st percentile of its 52-week range (Range: $211.43 - $343.12).

💰 Valuation Insight

BIO trades at a 59.9% discount (PE: 10.03), which may represent a value opportunity given the sector average of 25.00. Analysts anticipate some earnings pressure, with a higher forward PE.

🏥 Financial Health

Profit Margin Excellent
Debt/Equity Excellent
🔴 Revenue Growth Weak
🔴 Return on Equity Weak
⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap
$7.54B
Trailing P/E
10.03
Forward P/E
24.61
Beta (5Y)
1.16
52W High
$343.12
52W Low
$211.43
Avg Volume
298K
Day High
Day Low
Get BIO Z-Score on Dashboard 🚀